Episode 282
Emmet and Mike are back to discuss the latest stock market moves.
Mike breaks down the U.S. government’s attempts to reduce reliance on foreign companies by investing in homegrown alternatives. The ra…
Published on 2 months, 2 weeks ago
Episode 281
This week, Emmet is joined by an absolute legend of investing — co-founder of The Motley Fool, David Gardner. David is here to discuss his new book, Rule Breaker Investing: How to Pick the Best Stock…
Published on 2 months, 3 weeks ago
Episode 276
This week, Mike and Emmet venture onto the shores of the healthcare industry to identify some potential hundred-baggers.
Emmet breaks down Oscar Health, a stock often discussed by investors on X and R…
Published on 2 months, 4 weeks ago
Episode 279
The Multibagger King returns to Stock Club. Chris Mayer, author of 100 Baggers: Stocks That Return 100-to-1 and How to Find Them, inspired the creation of our international portfolio, Nexus, which ai…
Published on 3 months, 1 week ago
Episode 278
If you’re fatigued with the Magnificent Seven and their eye-watering valuations, maybe it’s time to look at some smaller market caps.
Pieter Slegers, founder of Compounding Quality, is back to discuss…
Published on 3 months, 2 weeks ago
Episode 277
In 2023, you’d be hard-pressed to find a Wall Street analyst who wasn’t in love with Lululemon. The stock was a classic example of a long-term, buy-and-hold winner, with a strong brand, enviable prof…
Published on 3 months, 2 weeks ago
Episode 276
This week, we bring you a debate every investor has had over the last year: Is Tesla still a buy?
Mike starts off by breaking down the brand’s difficulties in Europe, with sales sliding across markets…
Published on 3 months, 4 weeks ago
Episode 275
Mike and Emmet are back from Investicon with two phenomenal stock picks shared by the event’s expert panel.
Mike breaks down Chapters Group (ETR: CHG), a vertical market software acquirer modeled afte…
Published on 4 months ago
We're discussing two very different stocks today on Stock Club. One is the hottest stock on the market and one of the few companies being absolutely transformed by AI. Up 500% in the last year and al…
Published on 4 months, 2 weeks ago
Episode 273
Novo Nordisk faced another tough earnings season, with the stock falling 30% after it revised its growth guidance due to increased competition from Eli Lilly and the (now-illegal) compounders. This h…
Published on 4 months, 3 weeks ago
If you like Podbriefly.com, please consider donating to support the ongoing development.
Donate